https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39575 Wed 27 Jul 2022 14:43:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38853 r = 0.3–0.5; P ≤ 0.05). Total ARCS predicts cognitive impairment with good sensitivity and specificity relative to the BICAMS tests (AUC = 0.8; P = 0.00045). Total ARCS detects higher levels of impairment than BICAMS in MS patients (44% versus 21%). The memory domain of the ARCS and the BVMT-R were the best predictors of employment status (OR = 1.12 and 1.14, P  < 0.05). Conclusion: BICAMS and ARCS have comparable sensitivity for cognitive impairment in MS. Memory assessment from either tests is the best predictor of employment status; however, the BICAMS is a better predictor of work productivity.]]> Wed 23 Nov 2022 15:41:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38878 n = 13) erythrocyte-derived (CD235a) extracellular particles were increased, while platelet-derived (CD41b), leukocyte-derived (CD45), and CD4⁺T cell-derived (CD4) extracellular particles were decreased compared to both healthy controls (n = 27) (p<0.05) and secondary progressive multiple sclerosis patients (n = 9) (p < 0.05). Endothelium-derived extracellular particles (CD146) were increased in stable relapsing-remitting multiple sclerosis patients (n = 17) compared to healthy controls (p < 0.05). Extracellular particles from several different cells of origin correlated with each other and clinical parameters (e.g. disease duration, number of relapses, EDSS), though clinical correlations did not withstand corrections for multiple comparisons. Conclusions: Concentrations of erythrocyte-, leukocyte-, and platelet-derived extracellular particles were altered in relapsing multiple sclerosis patients and endothelium-derived extracellular particles were increased in stable relapsing-remitting patients compared to healthy controls. Extracellular particles may provide insights into altered the crosstalk between peripheral blood cells in multiple sclerosis, which may lead to the discovery of novel therapeutic targets.]]> Wed 23 Feb 2022 11:05:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54877 Wed 20 Mar 2024 13:18:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48943 Wed 19 Apr 2023 13:52:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49147 Wed 07 Feb 2024 15:06:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38113 Wed 04 Aug 2021 11:40:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50909 Tue 29 Aug 2023 11:01:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39853 Tue 26 Jul 2022 10:28:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54315 Tue 20 Feb 2024 14:35:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31987 Tue 17 Apr 2018 09:47:46 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51306 Thu 31 Aug 2023 14:27:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37635 65% by area and 16/50 a low grade stenosis of between 40-65% by area compared to 1/50 low grade stenoses in this segment in the controls. The commonest cause of the stenosis was a giant arachnoid granulation. The optic nerve sheaths were larger in MS than controls (p=0.0006). Comparing MS patients with transverse sinus stenosis to those without, the pituitary height was 16% smaller and BMI 25% larger (p=0.02 and 0.003 respectively) Conclusion: In patients with MS, the reduction in venous sinus compliance is associated with venous outflow stenoses in the transverse sinuses which increases the upstream venous pressure and dilates the sagittal sinuses. This finding suggests a continuum exists between MS and idiopathic intracranial hypertension.]]> Thu 24 Mar 2022 11:30:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52643 Thu 19 Oct 2023 15:18:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50194 Thu 06 Jul 2023 15:51:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46199 Mon 14 Nov 2022 11:22:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54196 Mon 12 Feb 2024 14:43:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54178 Mon 12 Feb 2024 13:11:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54737 90 % accuracy in this cohort (AUC=0.92, SE=0.86 - 0.94). Conclusion: Multi-modal MRI signatures can predict cognitive decline in a cohort of pwMS over 5 years with high accuracy. Future studies will benefit from the inclusion of even more MR modalities e.g., functional MRI, quantitative susceptibility mapping, magnetisation transfer imaging, as well as other potential predictors e.g., genetic and environmental factors. With further validation, this signature could be used in future trials with high-risk patients to personalise the management of cognitive decline in pwMS, even in the absence of relapses.]]> Mon 11 Mar 2024 14:19:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39532 Mon 08 Aug 2022 11:20:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48646 Fri 24 Mar 2023 13:51:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54938 Fri 22 Mar 2024 14:32:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51536 Fri 08 Sep 2023 12:58:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51498 Fri 08 Sep 2023 11:55:55 AEST ]]>